CY1111445T1 - Μεθοδος παρασκευης ισοτονης υδατικης ενεσης ροπιβακαϊνης - Google Patents

Μεθοδος παρασκευης ισοτονης υδατικης ενεσης ροπιβακαϊνης

Info

Publication number
CY1111445T1
CY1111445T1 CY20111100313T CY111100313T CY1111445T1 CY 1111445 T1 CY1111445 T1 CY 1111445T1 CY 20111100313 T CY20111100313 T CY 20111100313T CY 111100313 T CY111100313 T CY 111100313T CY 1111445 T1 CY1111445 T1 CY 1111445T1
Authority
CY
Cyprus
Prior art keywords
preparation
ropivakaine
aquatic
injection
ropivacaine
Prior art date
Application number
CY20111100313T
Other languages
English (en)
Inventor
Christopher N Jobdevairakkam
Jagadeesh B Rangisetty
Original Assignee
Navinta, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111445(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Navinta, Llc filed Critical Navinta, Llc
Publication of CY1111445T1 publication Critical patent/CY1111445T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Παρασκευή ενός ενέσιμου διαλύματος ροπιβακαΐνης με διάλυση βάσης ροπιβακαΐνης σε υδατικό όξινο διάλυμα που έχει γραμμομοριακή αναλογία οξέος προς βάση ροπιβακαΐνης μεγαλύτερη από 1:1 μειώνει την ανάγκη για υδροχλωρικό ή μονοένυδρο υδροχλωρικό ενδιάμεσο στην βιομηχανική κατασκευή του ενεσίμου. Η ωσμωτικότητα μπορεί να ρυθμίζεται ως απαιτείται. Η περίσσεια του οξέος εξουδετερώνεται με μία βάση.
CY20111100313T 2005-05-25 2011-03-22 Μεθοδος παρασκευης ισοτονης υδατικης ενεσης ροπιβακαϊνης CY1111445T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/137,256 US20060270708A1 (en) 2005-05-25 2005-05-25 Novel process for preparation of isotonic aqueous injection of ropivacaine
EP06770886A EP1883392B1 (en) 2005-05-25 2006-05-22 Process for preparation of isotonic aqueous injection of ropivacaine

Publications (1)

Publication Number Publication Date
CY1111445T1 true CY1111445T1 (el) 2015-08-05

Family

ID=37027513

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100313T CY1111445T1 (el) 2005-05-25 2011-03-22 Μεθοδος παρασκευης ισοτονης υδατικης ενεσης ροπιβακαϊνης

Country Status (14)

Country Link
US (1) US20060270708A1 (el)
EP (1) EP1883392B1 (el)
JP (1) JP2008545694A (el)
AT (1) ATE492269T1 (el)
AU (1) AU2006251583A1 (el)
CA (1) CA2608730A1 (el)
CY (1) CY1111445T1 (el)
DE (1) DE602006019085D1 (el)
DK (1) DK1883392T3 (el)
ES (1) ES2358884T3 (el)
PL (1) PL1883392T3 (el)
PT (1) PT1883392E (el)
SI (1) SI1883392T1 (el)
WO (1) WO2006127639A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051144A1 (it) * 2005-06-17 2006-12-18 Molteni & C Dei Fratellei Alit "procedimento per la preparazione d'una soluzione iniettabile di (2s)-n-(2;6-dimetil-fenil)-1-propil-2-piperidincarbossiamide"
CN102697708A (zh) * 2012-04-17 2012-10-03 上海禾丰制药有限公司 盐酸罗哌卡因注射液及其制剂工艺
US11224593B2 (en) * 2015-07-13 2022-01-18 Neon Laboratories Limited Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
CN105816432B (zh) * 2016-03-24 2020-02-07 成都天台山制药有限公司 注射用冷冻干燥盐酸罗哌卡因组合物及其质量控制方法
CN106177970B (zh) * 2016-07-12 2019-09-17 扬子江药业集团有限公司 罗哌卡因注射用制剂及其制备方法和应用
AU2018265624A1 (en) * 2017-05-11 2019-12-05 Steadymed, Ltd. Enhanced solubility drug-containing formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797241A (en) * 1953-08-28 1957-06-25 Brown Charles Leslie Meredith Diethyl-glycinexylidide and process
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
US6156900A (en) * 1994-10-07 2000-12-05 Darwin Discovery Limited Racemization of precursors to levobupivacaine and analogues thereof
CA2200356C (en) * 1994-10-25 2007-07-31 Graham Anthony Charles Frampton Process for preparing levobupivacaine and analogues thereof
SE9501808D0 (sv) * 1995-05-16 1995-05-16 Astra Ab New process
PL328199A1 (en) * 1996-01-25 1999-01-18 Schering Ag Improved concentrated intravascular injection and infusion solutions
IL129951A0 (en) * 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
HU228143B1 (en) * 1997-11-19 2012-12-28 Darwin Discovery Ltd Anaesthetic formulation
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
US7247729B2 (en) * 2001-09-10 2007-07-24 Mercian Corporation Method for producing pipecolamide derivative

Also Published As

Publication number Publication date
SI1883392T1 (sl) 2011-07-29
DK1883392T3 (da) 2011-04-18
US20060270708A1 (en) 2006-11-30
EP1883392A2 (en) 2008-02-06
WO2006127639A2 (en) 2006-11-30
PL1883392T3 (pl) 2011-07-29
WO2006127639A3 (en) 2007-05-18
EP1883392B1 (en) 2010-12-22
ATE492269T1 (de) 2011-01-15
ES2358884T3 (es) 2011-05-16
DE602006019085D1 (de) 2011-02-03
CA2608730A1 (en) 2006-11-30
AU2006251583A1 (en) 2006-11-30
PT1883392E (pt) 2011-03-29
JP2008545694A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
CY1111445T1 (el) Μεθοδος παρασκευης ισοτονης υδατικης ενεσης ροπιβακαϊνης
HRP20202017T1 (hr) Sintetski međuprodukt koristan u dobivanju triazolopiridina inhibitora c-met
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
CY1106597T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με φαρμακευτικως αποδεκτο οξυ
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
MX337396B (es) Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
BR112013014715B8 (pt) processo para produzir um artigo oco polimérico
IN2012DN00765A (el)
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
UY32496A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-aril-metil]-heterobenzamida, su preparación y su aplicación en terapéutica.
MA32193B1 (fr) Procede de preparation de combretastatine
RU2008105019A (ru) N-замещенные 4-метил-2,6-дихлорникотиноил-мочевины в качестве антидотов 2,4-д на подсолнечнике
ECSP088170A (es) Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano, su preparación y su aplicación en terapéutica
RU2006128805A (ru) Способ получения 3-тиа-1,5-диазабицикло[4,3,1]декана и 5-[4-(1,3,5-дитиазинан-5-ил)бутил]1,3,5-дитиазинана
TH100658B (th) การเข้าสูตรเอเควียสโคลซาปีน
TH100658A (th) การเข้าสูตรเอเควียสโคลซาลปีน
ATE487711T1 (de) Verfahren zur herstellung von metallsalzen von losartan
TH106979A (th) อนุพันธ์ของแอลคิล พิริมิดิน-4-โอนที่ถูกแทนที่
TH108942B (th) เกลือของตัวยับยั้งเอนไซม์ชนิดใหม่นอกจากนั้นที่เปลี่ยนแองจิโอเทนซินด้วยกรดตัวให้ no กระบวนการเตรียมเกลือชนิดเหล่านั้นและองค์ประกอบที่เป็นเภสัชภัณฑ์ที่มีเกลือชนิดเหล่านั้น
TH86233A (th) อนุพันธุ์ไพริดาซีน